Lung Cancer Trials

warning: Creating default object from empty value in /mnt/target03/355193/355662/www.universitycancerinstitute.com/web/content/modules/taxonomy/taxonomy.pages.inc on line 33.

Merck EMR 100070-005

A phase III open-label, multicenter trial of Avelumab versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non-small-cell lung cancer

Merck EMR 100070-004

A phase III open-label, multicenter trial of Avelumab versus Docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet

Astellas ASP8273-CL-0302

An open label, randomized phase 3 efficacy study of ASP8373 vs. Erlotinib or Gefintinib in First-line Treatment of patients with Stage IIIB/IV Non-small cell Lung Cancer Tumors with EGFR activating mutations

Celgene ABI-007-NSCL-004

A phase II, single arm, open label, multi-center, safety and tolerability trial with nab-Paclitaxel (Abraxane) plus Carboplatin followed by nab-Paclitaxel monotherapy as first line treatment for subjects with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2.

Clinical Protocol TEVA TV1011-CL-303

A multinational, Randomized, Open-Label Phase III study of Custirsen (TV-1011/OGX-011) in combination with Docetaxel versus Docetaxel as a second-line treatment in patients with advanced or metastatic Stage IV Non Small Cell Lung Cancer.

Protocol Number: 20070782

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.

For More Information Please Contact

Tom Voulgaris
Director, Research Department

2240 W Woolbright Road
Suite 415
Boynton Beach, FL 33426

561-737-6556 (Office)
561-737-9244 (Fax)

Ranger Computer